A randomized phase 3 study comparing theefficacy and safety of gemcitabine (GEM) and irinotecan (I), to GEM alone in patients with locally advanced or metastatic pancreatic cancer who have not received prior systemic therapy. - Rocha-Lima,C.MS.; Rotche,R.; Jeffery,M. (Proc ASCO, 2003)